Psoriasis
Conditions
Keywords
Psoriasis
Brief summary
In recent years, biologics have changed the treatment of psoriasis, giving us additional therapeutic options that are potentially less toxic to the liver, kidneys, and bone marrow and are not teratogenic. Nevertheless, traditional systemic therapies continue to play an important role in the treatment of psoriasis in Turkey, even in patients who are requiring biologic treatments according to national recommendations. This study is designated to observe the effectiveness and safety of tumor necrosis factor inhibitors in patients with moderate to severe psoriasis.
Detailed description
Patients admitted to dermatology clinics, with moderate to severe psoriasis for whom the physician has decided to initiate psoriasis treatment with anti-TNFs in accordance with Turkish Ministry of Health regulations and reimbursements. (Tumor necrosis factor inhibitors can be used for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or Psoralen Ultra-Violet A. Patients should be screened for latent tuberculosis and appropriate anti-tuberculosis prophylaxis must be initiated if latent tuberculosis is diagnosed). This is a national, multi-center, observational, prospective photographic atlas study in patients who are treated with tumor necrosis factor inhibitors for moderate to severe psoriasis in daily clinic according to Turkish regulations and reimbursement. Demographic data will be collected by the investigator at the beginning of the study. Every participant will be examined by the investigator and the Psoriasis Area Severity Index will be determined at the beginning of the study and at weeks 4, 8, 16 and 24. Each patient will be asked to fill out the Dermatology Life Quality Index at each visit. Each patient will be asked to fill out the Work Productivity and Activity Impairment Questionnaire: Psoriasis at the beginning and last visit (week 24). A standardized set of photographs will be taken at the beginning of the study and at weeks 4, 8, 16 and 24 by a dermatologist trained about standardized photograph positioning and settings. Psoriasis Area Severity Index, Dermatology Life Quality Index and Photographic scores will be statistically analyzed separately in order to evaluate treatment response.
Interventions
None listed
Sponsors
Abbott
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients ≥18 years old with moderate-to-severe psoriasis. * Patients for whom the physician has decided to initiate psoriasis treatment with anti-TNFs in accordance with Turkish Ministry of Health regulations and reimbursements. * Patients who are able to understand and answer a self administered questionnaire. * Patients signed an informed consent form stating that they agreed to have their photographs taken, analyzed, and included in a scientific publication.
Exclusion criteria
* Patients who do not consent to being photographed during the study. * Females who are pregnant, nursing, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study. * Patients with untreated tuberculosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score | Baseline and Weeks 4, 8, 16 and 24 | The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Baseline is presented as a percentage of the Baseline value: Baseline value - post-baseline value / Baseline value \* 100. |
| Percentage of Participants With 75% Reduction in PASI Score | Baseline and Weeks 4, 8, 16 and 24 | The percentage of participants with a 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. The score ranges from 0 (best outcome) to 72 (worst outcome). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Static Physician Global Assessment (PGA) of Psoriasis | Baseline and Week 24 | In the static physician assessment of psoriasis, psoriasis severity was rated first for all Baseline photographs and then for all Week 24 photographs according to the following scale: Clear (no lesion); Psoriasis almost cleared; Mild psoriasis; Mild to moderate psoriasis; Moderate psoriasis; Moderate to severe psoriasis; Severe psoriasis. |
| Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score | Baseline and Weeks 4, 8, 16 and 24 | The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline is presented as a percentage of the Baseline value: Baseline value - post-baseline value / Baseline value \* 100. |
| Dynamic Physician Global Assessment (PGA) of Change in Psoriasis | Baseline and Week 24 | In the dynamic physician global assessment of change in psoriasis, the physician compared sets of standardized photographs taken at Baseline and at Week 24 for each participant and rated the change of psoriasis severity on the dynamic PGA scale from -5 (considerable deterioration), 0 (no or minimal change) to +5 (considerable improvement). |
| Number of Participants With Adverse Events (AEs) | 24 Weeks | The number of participants experiencing any adverse event or a serious adverse event during the study are summarized. A serious AE is an event that results in death, is life-threatening, requires or prolongs hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity or is an important medical event that may require medical or surgical intervention to prevent any of the outcomes listed above. Please see the Adverse Event module below for additional details. |
| Percent Change From Baseline in Work Productivity and Activity Impairment | Baseline and Week 24 | The following parameters were assessed using the Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO): * Percent work time missed in the last 7 days due to problems associated with psoriasis; * Percent impairment at work, based on the participant's assessment of how much psoriasis affected their productivity while they were working in the last 7 days; * Percent overall loss of work productivity, based on hours missed and impairment while working due to psoriasis; * Percent general activity impairment, based on the participant's assessment of how much psoriasis affected their ability to perform regular daily activities, such as work around the house, shopping, child care, exercising, studying, etc. Each domain score ranges from 0 (no impairment) to 100 (complete impairment). Change from Baseline is presented as a percentage of the Baseline value: Baseline value - post-baseline value / Baseline value \* 100. |
| Dynamic Patient Global Assessment (PGA) of Change in Psoriasis | Baseline and Week 24 | In the dynamic patient global assessment of change in psoriasis, the participant compared their own sets of standardized photographs taken at Baseline and at Week 24 and rated the change of the severity of psoriasis using the dynamic photographic scale adapted to a visual analog scale ranging from -5 (very large deterioration) to +5 (very large improvement). |
Countries
Turkey (Türkiye)
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Anti-TNF Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor (anti-TNF) agent prior to enrollment according to national approved indications and reimbursement guidelines. | 103 |
| Total | 103 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Investigator decision | 4 |
| Overall Study | Non-compliance | 1 |
| Overall Study | Not eligible for the study | 2 |
| Overall Study | Serious adverse event | 1 |
| Overall Study | Withdrawal by Subject | 9 |
Baseline characteristics
| Characteristic | Anti-TNF |
|---|---|
| Age Continuous | 44.9 years STANDARD_DEVIATION 13.9 |
| Body Mass Index (BMI) | 29.3 kg/m^2 STANDARD_DEVIATION 14.9 |
| Dermatology Life Quality Index (DLQI) Score | 15.1 scores on a scale STANDARD_DEVIATION 7.3 |
| Duration of Psoriasis | 15.7 years STANDARD_DEVIATION 9.2 |
| Gender Female | 40 participants |
| Gender Male | 62 participants |
| Height | 166.9 cm STANDARD_DEVIATION 13.5 |
| Psoriasis Area and Severity Index (PASI) Score | 20.8 scores on a scale STANDARD_DEVIATION 11.2 |
| Region of Enrollment Turkey | 103 participants |
| Weight | 78.5 kg STANDARD_DEVIATION 16 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 7 / 103 |
| serious Total, serious adverse events | 3 / 103 |
Outcome results
Primary
Percentage of Participants With 75% Reduction in PASI Score
The percentage of participants with a 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. The score ranges from 0 (best outcome) to 72 (worst outcome).
Time frame: Baseline and Weeks 4, 8, 16 and 24
Population: Participants who received treatment with anti-TNF agents and completed study follow-up visits through to Week 24.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Anti-TNF | Percentage of Participants With 75% Reduction in PASI Score | Week 4 | 31.4 percentage of participants |
| Anti-TNF | Percentage of Participants With 75% Reduction in PASI Score | Week 8 | 51.2 percentage of participants |
| Anti-TNF | Percentage of Participants With 75% Reduction in PASI Score | Week 16 | 67.4 percentage of participants |
| Anti-TNF | Percentage of Participants With 75% Reduction in PASI Score | Week 24 | 70.9 percentage of participants |
Primary
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Baseline is presented as a percentage of the Baseline value: Baseline value - post-baseline value / Baseline value \* 100.
Time frame: Baseline and Weeks 4, 8, 16 and 24
Population: Participants who received treatment with anti-TNF agents and completed study follow-up visits through to Week 24.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Anti-TNF | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score | Week 4 | 48.65 Percent change | Standard Deviation 36.27 |
| Anti-TNF | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score | Week 8 | 75.70 Percent change | Standard Deviation 36.11 |
| Anti-TNF | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score | Week 16 | 87.85 Percent change | Standard Deviation 36.91 |
| Anti-TNF | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score | Week 24 | 90.29 Percent change | Standard Deviation 25.49 |
Secondary
Dynamic Patient Global Assessment (PGA) of Change in Psoriasis
In the dynamic patient global assessment of change in psoriasis, the participant compared their own sets of standardized photographs taken at Baseline and at Week 24 and rated the change of the severity of psoriasis using the dynamic photographic scale adapted to a visual analog scale ranging from -5 (very large deterioration) to +5 (very large improvement).
Time frame: Baseline and Week 24
Population: Participants who received treatment with anti-TNF agents and completed study follow-up visits through to Week 24.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anti-TNF | Dynamic Patient Global Assessment (PGA) of Change in Psoriasis | 1.51 scores on a scale | Standard Deviation 2.26 |
Secondary
Dynamic Physician Global Assessment (PGA) of Change in Psoriasis
In the dynamic physician global assessment of change in psoriasis, the physician compared sets of standardized photographs taken at Baseline and at Week 24 for each participant and rated the change of psoriasis severity on the dynamic PGA scale from -5 (considerable deterioration), 0 (no or minimal change) to +5 (considerable improvement).
Time frame: Baseline and Week 24
Population: Participants who received treatment with anti-TNF agents and completed study follow-up visits through to Week 24.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Anti-TNF | Dynamic Physician Global Assessment (PGA) of Change in Psoriasis | 1.51 scores on a scale | Standard Deviation 2.24 |
Secondary
Number of Participants With Adverse Events (AEs)
The number of participants experiencing any adverse event or a serious adverse event during the study are summarized. A serious AE is an event that results in death, is life-threatening, requires or prolongs hospitalization, is a congenital anomaly, results in persistent or significant disability/incapacity or is an important medical event that may require medical or surgical intervention to prevent any of the outcomes listed above. Please see the Adverse Event module below for additional details.
Time frame: 24 Weeks
Population: All enrolled participants.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Anti-TNF | Number of Participants With Adverse Events (AEs) | Any adverse event | 28 participants |
| Anti-TNF | Number of Participants With Adverse Events (AEs) | Serious adverse event | 3 participants |
Secondary
Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline is presented as a percentage of the Baseline value: Baseline value - post-baseline value / Baseline value \* 100.
Time frame: Baseline and Weeks 4, 8, 16 and 24
Population: Participants who received treatment with anti-TNF agents and completed study follow-up visits through to Week 24.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Anti-TNF | Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score | Week 4 | 53.13 percent change |
| Anti-TNF | Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score | Week 8 | 66.40 percent change |
| Anti-TNF | Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score | Week 16 | 73.98 percent change |
| Anti-TNF | Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score | Week 24 | 65.72 percent change |
Secondary
Percent Change From Baseline in Work Productivity and Activity Impairment
The following parameters were assessed using the Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO): * Percent work time missed in the last 7 days due to problems associated with psoriasis; * Percent impairment at work, based on the participant's assessment of how much psoriasis affected their productivity while they were working in the last 7 days; * Percent overall loss of work productivity, based on hours missed and impairment while working due to psoriasis; * Percent general activity impairment, based on the participant's assessment of how much psoriasis affected their ability to perform regular daily activities, such as work around the house, shopping, child care, exercising, studying, etc. Each domain score ranges from 0 (no impairment) to 100 (complete impairment). Change from Baseline is presented as a percentage of the Baseline value: Baseline value - post-baseline value / Baseline value \* 100.
Time frame: Baseline and Week 24
Population: Participants who received treatment with anti-TNF agents and completed study follow-up visits through to Week 24. The first 3 domains (work time missed, work impairment and overall loss of work productivity) were assessed on a sub-group of participants who had full time jobs (n=30).
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Anti-TNF | Percent Change From Baseline in Work Productivity and Activity Impairment | Work time missed | 96 percent change |
| Anti-TNF | Percent Change From Baseline in Work Productivity and Activity Impairment | Impairment at work | 72 percent change |
| Anti-TNF | Percent Change From Baseline in Work Productivity and Activity Impairment | Overall loss of work productivity | 75 percent change |
| Anti-TNF | Percent Change From Baseline in Work Productivity and Activity Impairment | Activity impairment | 72 percent change |
Secondary
Static Physician Global Assessment (PGA) of Psoriasis
In the static physician assessment of psoriasis, psoriasis severity was rated first for all Baseline photographs and then for all Week 24 photographs according to the following scale: Clear (no lesion); Psoriasis almost cleared; Mild psoriasis; Mild to moderate psoriasis; Moderate psoriasis; Moderate to severe psoriasis; Severe psoriasis.
Time frame: Baseline and Week 24
Population: Participants who received treatment with anti-TNF agents and completed study follow-up visits through to Week 24.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Anti-TNF | Static Physician Global Assessment (PGA) of Psoriasis | Psoriasis almost clear | 0 participants |
| Anti-TNF | Static Physician Global Assessment (PGA) of Psoriasis | Mild to moderate psoriasis | 1 participants |
| Anti-TNF | Static Physician Global Assessment (PGA) of Psoriasis | Clear psoriasis | 0 participants |
| Anti-TNF | Static Physician Global Assessment (PGA) of Psoriasis | Moderate psoriasis | 35 participants |
| Anti-TNF | Static Physician Global Assessment (PGA) of Psoriasis | Mild psoriasis | 0 participants |
| Anti-TNF | Static Physician Global Assessment (PGA) of Psoriasis | Moderate to severe psoriasis | 27 participants |
| Anti-TNF | Static Physician Global Assessment (PGA) of Psoriasis | Severe psoriasis | 23 participants |
| Week 24 | Static Physician Global Assessment (PGA) of Psoriasis | Moderate to severe psoriasis | 3 participants |
| Week 24 | Static Physician Global Assessment (PGA) of Psoriasis | Severe psoriasis | 0 participants |
| Week 24 | Static Physician Global Assessment (PGA) of Psoriasis | Clear psoriasis | 14 participants |
| Week 24 | Static Physician Global Assessment (PGA) of Psoriasis | Psoriasis almost clear | 38 participants |
| Week 24 | Static Physician Global Assessment (PGA) of Psoriasis | Mild psoriasis | 19 participants |
| Week 24 | Static Physician Global Assessment (PGA) of Psoriasis | Mild to moderate psoriasis | 4 participants |
| Week 24 | Static Physician Global Assessment (PGA) of Psoriasis | Moderate psoriasis | 8 participants |